ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LENZ vs BDTX // OPERATING MARGIN

LENZ Therapeutics Inc. (NASDAQ) VS. Black Diamond Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LENZ 1 — BDTX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LENZ VS. BDTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LENZ BDTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -27.80% 10.80% -38.60 BDTX /roic <GO>
EV/EBITDA & P/E Valuation — 6.9x — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.19 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 BDTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.8 45.4 -9.59 BDTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $109.7M $106.9M $2.8M LENZ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LENZ REV BDTX REV LENZ GROSS % BDTX GROSS % LENZ FCF BDTX FCF
FY 2025 $19.1M $0 97.8% — -$70.0M $29.6M
FY 2024 $0 $0 — — -$59.9M -$62.3M
FY 2023 $0 $0 — — -$60.4M -$66.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LENZ // BETA —
BDTX // BETA —